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Medicinal herbs play an important role in the primary health care system of developing countries and always uphold the 
importance of ethnomedicinal studies in the drug discovery process. Indian Siddha practitioners urged people to consume a 
polyherbal formulation named ‘Kaba Sura kudineer (KSK)’ as a prophylactic measure against COVID-19. To validate the 
presence of anti-COVID 19 agents if any in KSK, virtual screening of 80 phytochemicals was done by blind docking, fixing 
the RBD-ACE2 complex as the target using PyRx software. The binding energy of the compounds was calculated using 
Autodock Vina. The SWISSADME server was used to identify the phytochemicals that obey the Lipinski rule and the 
blood-brain barrier permeability of the compounds. The outcome of the study revealed that phytochemicals such as 
diosgenin, diosgenone, coumaperine, bisdemethoxycurcumin, tinocordifolin, isovanillinand 1,8-Cineole displayed hydrogen 
bond interactions with the complex residues in the interacting site (−8.9 to −5.1 kcal/mol) and were found to obey the 
Lipinski rule as well as possess blood-brain barrier (BBB) permeability. Based on the highest docking score and the more 
number of interacting residues at the active site herein we suggest diosgenin and bisdemethoxycurcumin as potential 
inhibitors of SARS-Co-V-2.  
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The World Health Organization (WHO) dashboard 
revealed that 93,805,612 confirmed cases of COVID-
19, including 2,026,093 deaths, have been reported 
worldwide as of 18th January, 2021. In India, from 3 
to 18 January, 2021, there have been 10,571,773 
confirmed cases of COVID-19 with 152,419 deaths as 
per the data available (https://covid19.who.int/ 
region/searo/country/in). Medicinal herbs play an 
important role in the primary health care system of 
developing countries like India and always uphold the 
importance of ethnomedicinal studies in the drug 
discovery process. Antiviral drug discovery is always 
challenging as it poses a threat to the people who 
come in contact with the virus. For a virus that 
becomes pandemic, the challenges become multifold. 
Medicinal plants contain extractable biochemical and 
bioactive compounds, which can target certain viruses 
or can cure or prevent several viral diseases and 
infections1. Ayurveda and Siddha practices that 
originated in ancient India are still being widely used 
by both the rural and urban communities in various 
parts of the country. With the application of modern 
science and technology, it is plausible to effectively 
characterize bioactive and thereby the medicinal herbs 
as anti-infective agents. It will also uphold the value 
of traditional medicine which will be cost-effective 
with less or no adverse effects. 
Kaba Sura Kudineer (KSK), is an Indian Siddha 
formulation that was highly valued by the 
Government of Tamil Nadu, India in their campaign 
as a prophylactic agent, as the government believed 
prevention is better than cure. Ministry of Ayush 
India, recommended KSK, as an add-on intervention 
to conventional care in the management of COVID-
19(2). In the name Kaba Sura Kudineer (KSK) the 
term kabam means ‘cold/phlegm’ and suram means ‘a 
fever’, People across Tamil Nadu were directed to 
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consume this KSK as it was claimed to boost the 
immune system due to the presence of fifteen herbs 
with potent pharmacological properties. However, the 
efficacy of KSK against COVID-19 and whether the 
formulation possesses any anti-viral property or 
agents against SARS-CoV-2 is yet to be validated. 
The present study is aimed to discover whether any of 
the phytoconstituents that present in this herbal 
formulation could exhibit anti- SARS-CoV-2 
properties by performing in silico molecular 
interactions between the phytochemical (ligand) and 
RBD-ACE2 complex (target). This is the first study 
that employed the whole RBD-ACE2 complex as a 
target to screen phytochemicals from KSK and uses 
the Lipinski rule to identify drug-like molecules. 
 
Materials and Methods 
 
Drug target preparation 
To study the inhibitory effect of Kaba Sura 
Kudineer (KSK) against SARS-CoV-2 and ACE2 
(Angiotensin-converting Enzyme-2) interaction, the 
complex structure of SARS-CoV-2 spike receptor-
binding domain with ACE2 was considered. The 
crystal structure of the complex was taken from the 
RCSB (6M0J.pdb)3. The sequence length of ACE2 
was 603 while that of spike RBD was 229. The 
ligands present in the crystal structure, namely NAG, 
ZN and CL, were removed. The missing residues in 
ACE2 (616-621) and RBD (319-332 and 527-547) 
were added using CHARMM-GUI4. The 
macromolecular complex structure was prepared for 
molecular docking in the PyRx software5. The 
interaction between the protein ACE2 and spike RBD 
was calculated using PDBSum6 (Table 1).  
 
Ligand preparation 
The key compounds present in each ingredient of 
KSK mentioned in (Supplementary material)  
Table S1 were considered for virtual screening. There 
were a total of 109 molecules and the available 3D 
structures for these molecules resulted in 80 being 
taken from PubChem7 in the single SDF file format.  
 
Molecular docking using Autodock Vina in PyRx and drug 
properties 
After the preparation of macromolecule and ligand, 
blind docking was performed for 80 molecules against 
the complex using PyRx software. The parameters set 
are the conjugate gradient (CG) optimization of 15000 
steps. The grid dimensions were set at a maximum of 
61.7Å x 72.1Å x140.9Å with a grid center defined at 
−26.57,+17.94,−11.63 in X, Y, Z directions, 
respectively. The molecules which pose in the 
interacting site of ACE2-spike RBD were considered 
for further analysis. The binding energy of the 
compounds was calculated using AutodockVina8, the 
available module in PyRx software. Figure 1 shows 
the molecular docking workflow to identify the 
effective phytochemicals in blocking the ACE2 and 
RBD interactions. 
 
Lipinski rule and drug-likeness calculations 
The SWISSADME server9 was used to identify the 
phytocompounds that obey the Lipinski rule and have 
the blood-brain barrier permeability.  
 
Results  
Identification and optimization of the lead 
compounds present in KSK were performed through 
blind docking. Initially, the 3D structures of 80 
compounds found in KSK were retrieved from the 
PubChem database and were blindly docked with the 
RBD-ACE2 complex as the target. Among these 80 
compounds, only 18 compounds were found to be 
docked in the interacting site of RBD and ACE2 with 
binding affinity ranging from −12.5 to −3.3 kcal/mol 
(Table 2). It was observed that some molecules with 
good binding affinity were not having the perfect pose 
and those with good binding pose had a 
comparatively lower binding affinity.  
Table 1 — The residues in human ACE2 interacting with the 
residues in RBD 
S.No ACE2 RBD 
1 Glu35 Gln493 
2 Lys31 Gln493 
3 Asp30 Lys417 
4 Gln24 Ala475, Asn487 
5 Tyr83 Asn487, Phe486, Tyr489 
6 Met82 Phe486 
7 Leu79 Phe486 
8 Phe28 Tyr489 
9 Thr27 Tyr489, Phe456 
10 His34 Tyr453, Leu455 
11 Arg393 Tyr505 
12 Glu37 Tyr505 
13 Gly354 Tyr505, Gly502 
14 Lys353 Tyr505, Gly502, Gly496, Asn501 
15 Asn330 Thr500 
16 Arg357 Thr500 
17 Tyr41 Asn501, Thr500, Gln498 
18 Asp355 Thr500 
19 Gln42 Gln498, Gly446, Tyr449 
20 Asp38 Tyr449 




After filtering the compounds in the SWISSADME 
server, only 7 phytochemicals were found to obey the 
Lipinski rule and BBB permeability. Table 3 gives 
Lipinski's rule of five attributes for the selected 7 
phytochemicals. The docked pose of the seven 
compounds was further analyzed and their binding 
affinity ranged from −8.9 to −5.1 kcal/mol. Each of 
these seven compounds has 1 to 5 hydrogen bond 
interactions and from 27 to 41 close-contacts with the 
complex in the interacting site, substantiating the 
inhibitory property of these ligands on RBD and 
ACE2 complex formation a vital initial step in SARS-
COV2 infection. The compounds inhibiting the 
interaction of ACE2 and RBD were tabulated in  
Table 4. Further analysis revealed that these seven 
molecules displayed hydrogen bond interactions with 
the complex residues in the interacting site. Though 
the findings provide concrete information on the 
inhibitory property of these seven compounds in the 
formation of the RBD-ACE complex, the 
investigations on the dynamics of the phytochemicals 
in the complex structure will provide an in-depth 
understanding of this interaction mechanism between 
ligand and RBD-ACE2 complex and the dynamics 
study will be done in near future.  
Tracing of those compounds based on their binding 
affinity, using their PubChem ID led to the 
identification of seven ligands viz., diosgenin (−8.9 
kcal/mol), diosgenone (−8.7 kcal/mol), coumaperine 
(−6.7 kcal/mol), bisdemethoxycurcumin (−6.6 
kcal/mol), tinocordifolin (−6.4 kcal/mol), isovanillin 
(−5.2 kcal/mol) and 1,8-Cineole (−5.1 kcal/mol). 
Figure 2 shows the binding pose of the ligands with 
the target complex. From Table 1, it was clear that the 
residues Y41 and K353 present in ACE2 were found 
to have strong interactions with the residues in RBD. 
The phytochemicals were found to have 27 to 38 
strong interactions with the complex. Further ranking 
of phytochemicals revealed diosgenin and 
 
 
Fig. 1 — Shows the workflow of the molecular docking of 
phytochemicals to the ACE2-RBD complex. 
 
Table 2 — Binding energy of the ligand to the interacting site of 
ACE2-RBD complex after blind docking 
Name Pubchem ID Binding Energy 
(kcal/mol) 
Serratagenic Acid 21594175  −12.5 
Isovanillin 12127 −5.2 
Coumaperine* 10131321 −6.7, −6.5, −6.4 
Pyrrolidine 31268 −3.3 
Bisdemethoxycurcumin 5315472 −6.6 
Sitosterol-D-Glucoside* 71628 −7.7, −7.6 
Iridin* 5281777 −8.0, −7.5 
Quercetin-3-O-Rutinoside 5280805 −8.2 
Tinocordifolin 100926540 −6.4 
α-cis-Bergamotene 6429303 −6.2 
1,8-Cineole 2758 −5.1, −4.6 
Diosgenin* 99474 −8.9, −8.4 
Diosgenone 10251134   −8.7 
Lupeol 259846  −8.6 
Chebulinic Acid 72284   −9.7 
Casuarinin 157395 −10.6 
Terchebulin* 16175789 −10.1,−9.8 
Terflavin A 16175788  −10.2 
*Ligand showing more than one pose interacts with the complex
site and their energy for each site is given. 
Table 3 — The Lipinski's rule of five for the 7 phytochemicals 
Phytochemicals miLogP TPSA natoms MW nON nOHNH 
Diosgenin 4.52 38.69 30 414.62 3 1 
Diosgenone 4.38 35.53 30 412.6 3 0 
Coumaperine 2.84 40.54 19 257.33 2 1 
Bisdemethoxycurc
umin 
1.75 74.6 23 308.33 4 2 
Tinocordifolin 2.68 49.83 18 250.33 3 1 
Isovanillin 1.44 46.53 11 152.15 3 1 
1,8-Cineole 2.58 9.23 11 154.25 1 0 
 




bisdemethoxycurcumin as potential anti-SARS Co-V-




The novel coronavirus disease (COVID 19) caused 
by the SARS-Co-V-2 remains in upsurge day by day 
increasing the morbidity and mortality mostly due to 
lung pathology10. In humans, transmission occurs via 
droplets as with other respiratory viruses and the virus 
is reported to survive on different surfaces for days 
and remains alive in aerosols for hours11. WHO insists 
to follow frequent personal hygiene and social 
distancing to minimize viral exposure. The infection 
rate of nSARS-COV2 outstripped the previous 
outbreak caused by the SARS-COV and MERS-COV 
though COVID-19 has many clinical features similar 
to SARS. It has been established that SARS-COV2 
shares sequence homology with the SARS-COV and a 
bat coronavirus12. Despite its analogy to SARS-COV, 
the transmission efficiency and diagnostic methods of 
SARS-COV2 are rather contrasting which is probably 
due to the nucleotide changes in the spike (S) protein 
and its receptor-binding domain (RBD) which makes 
the drug development strategy an arduous one.  
Like the other members of the coronavirus family 
that caused SARS and MERS, SARS-Co-V2 is also 
shown to use the angiotensin-converting enzyme 2 
(ACE2) a member of the ACE family of dipeptidyl-
carboxydipeptidase and is highly homologous to 
ACE1 as its receptor for infecting humans13. The 
report showed that the ACE2-binding affinity of the 
receptor-binding domain (RBD) in the S1 subunit of S 
protein of SARS-CoV-2 is 10 to 20 fold higher than 
that of SARS-CoV14. The signature spike protein 
named S protein comprising two subunits S1 and S2 
of the coronavirus is the key for the viral entry into 
human cells via ACE2. This is initiated by the RBD 
of the S1 subunit in S protein, followed by the self-
folding of the S2 subunit that brings the interaction of 
the heptad repeat 1 (HR1) and 2 (HR2) domains of 
the S2 subunit forming a six-helix bundle (6-HB) 
fusion core that facilitates the proximity of the viral 
and cellular membranes for fusion and infection15. 
Infection of SARS-CoV-2 is reported to down-
regulate ACE2 expression in lung cells causing 
dysfunction of the renin-angiotensin system that 
 
 
Fig. 2 — Depicts the interaction of the ligands in the interacting
site of the ACE2-RBD complex a) Diosgenin b) Diosgenone
c) Coumaperine d) Bisdemethoxycurcumin e) Tinocordifolin
f) Isovanillin and g) 1,8-Cineole respectively. The interacting
residues in ACE2 (chain A: Green) and RBD (chain E: Light
Brown) are shown. 
Table 4 — Binding affinity of the phytochemicals to the interacting site of ACE2-RBD complex 
Name Pubchem ID Binding affinity 
(kcal/mol) 
Rank Total number of interactions with the complex 
residues 
Diosgenin 99474 −8.9 1 38 (E: Gly485, Cys488)* 
Diosgenone 10251134   −8.7 2 36 (A: Asn49, Lys68)* 
Coumaperine 10131321 −6.7 3 33 (A: Asn33, Lys353; E:Gly496)* 
Bisdemethoxycurcumin 5315472 −6.6 4 33 (A: Arg393; E: Gln409, Gly496, Tyr505)* 
Tinocordifolin 100926540 −6.4 5 33 (A: Gln76)* 
Isovanillin 12127 −5.2 6 32 (A: Gln76; E: Asn487, Tyr489)* 
1,8-Cineole 2758 −5.1 7 27 (A: Gln76)* 
*Intermolecular hydrogen bond interaction of lead compounds with chain A (ACE2) and chain E (RBD) is given. 




results in the disturbances of blood pressure, 
fluid/electrolyte balance associated with increased 
inflammation and vascular permeability in the 
airways16. Drug development strategies targeting the 
RBD-ACE2 complex will be of great potential as the 
mechanism of cell entry reveals that the formation of 
the RBD-ACE2 complex is the initial step of 
infection.  
Drug repurposing is an effective strategy in 
discovering or developing drug molecules with new 
pharmacological targets or therapeutic indications. As 
drug repurposing helps to overcome the issues 
associated with preclinical development and 
optimization, it saves time and reduces expenses as 
well as failures typically associated with the drug 
discovery process17. The application of computer-
aided drug design also potentiates drug repurposing as 
it gives cues about the functional probability of the 
drugs. In drug repurposing, structure-based 
approaches have been extensively used to analyze and 
predict the activity of ligands using proteins as 
targets. In the current COVID-19 scenario, where 
there is an accelerated drug discovery process as no 
proper drug is identified yet to fight against SARS-
Co-V-2, this computer-aided drug discovery becomes 
indispensable due to time constraints. Molecular 
docking, a versatile tool used to predict the geometry 
and to score the interaction of a protein in complex 
with a small-molecule ligand18 is employed in the 
present study to identify the anti-SARS-Co-V-2 
phytochemical from the herbs of KSK targeting RBD-
ACE2 complex genesis a key process involved in the 
mechanism of cell entry by SARS-Co-V-2.  
Among these phytochemicals, the first two ranked 
compounds diosgenin and diosgenone were from the 
herb Costus speciosus (Koen Ex. Retz) Sm. (Family-
Costaceae) (Venkottam/ Crepe Ginger) and the next 
two compounds Coumaperine and 
Bisdemethoxycurcumin were from the herb Piper 
longum L. (Thippili/ Long pepper). While the other 
compounds tinocordifolin, isovanillin, and 1, 8-Cineole 
was from three different herbs Tinospora cordifolia 
(Willd.) Miers, Zingiber officinale Roscoe and Cyperus 
rotundus Lrespectively. Diosgenin (C27H42O3) a C27 
spiroketal steroid sapogenin belonging to a family of 
spirostanol steroidal compounds has the highest 
docking score. Other than Costus speciosus used in the 
polyherbal formulation KSK, diosgenin is also present 
in several plants, namely Dioscorea spp., Trigonella 
spp., and Smilax spp. A series of preclinical and 
mechanistic studies have been performed to understand 
the real importance and benefits of diosgenin against a 
variety of pathologies including metabolic diseases 
(diabetes, obesity and dyslipidemia, including 
hypercholesterolemia), inflammatory diseases, and 
cancer as reviewed by Jesus19. Diosgenin resembles the 
steroidal structure of glucocorticoids like 
dexamethasone, a synthetic glucocorticoid with anti-
inflammatory and immunosuppressant activities. 
Junchao et al.20, reported that diosgenin, by its ability 
to induce the expression of glucocorticoid receptors 
(GRs), downregulated the pro-inflammatory cytokines 
TNF-a, IL-1b and IL-6 and exhibited anti-
inflammatory effects in the trachea of asthmatic mice. 
Though diosgenin displayed the highest score and 
active site interaction with RBD-ACE amino acid 
residues Gly485, Cys488) followed by its derivative 
diosgenone, the phytochemical bisdemethoxycurcumin 
also presents as a potential anti-COVID-19 agent 
because of its ability to interact with four amino acid 
residues (Arg393; Gln409, Gly496, Tyr505 in RBD). 
Bisdemethoxycurcumin, from Piper longum used in 
the polyherbal formulation KSK is well known as an 
active ingredient of Curcuma longa, had already been 
reported to suppress TNF-induced NF-κB activation a 
key inflammatory signaling pathway21. 
Bisdemethoxycurcumin interacts strongly with Tyr505, 
a key residue in RBD that interacts strongly with the 
residues Glu37, Lys353, Gly354 and Arg393 in ACE2. 
These findings substantiate that this polyherbal 
formulation might act against SARS-Co-V2 infection. 
The majority of the Indian population relies on 
medicinal herbs as they are a good alternate for curing 
many diseases22. However considerable knowledge 
accumulated by the villagers and tribals on herbal 
medicine remains unknown to the scientists23 and 
hence these herbal remedies must undergo preclinical 
and clinical investigations to establish their immense 
therapeutic value. In this context, our preliminary 
findings open a novel perspective to test diosgenin and 
bisdemethoxycurcumin either as an individual or as 




In silico screening of key phytochemicals from the 
medicinal herbs of a polyherbal formulation “Kaba 
Sura Kudineer” identified seven phytochemicals as 
drug-like candidates. Out of seven, based on the high 
molecular docking score and the more number of 




interaction residues, the two phytochemicals 
diosgenin from Costus speciosus and 
bisdemethoxycurcumin from Piper longum are 
suggested as potential inhibitors and the findings 
warrant appropriate preclinical and clinical 
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